Martin Schaefer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Martin Schaefer has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
Astrid Friebe
3 shared publicationsRahul Sarkar
Department of Psychiatry and Psychotherapy, Asklepios Westklinikum Hamburg-Klinikum, Germany
3 shared publications- Andreas Heinz
Department of Psychiatry and Psychotherapy, Technische Universität Dresden, Dresden, Germany
2 shared publications - Annett Lotzin
Department of Psychiatry and Psychotherapy, University Medical Center Hamburg-Eppendorf, Hamburg, Germany
2 shared publications - Barbara Schneider
Michigan State University
2 shared publications - Crisanto Diez-Quevedo
Heart Failure Clinic and Cardiology Service, University Hospital Germans Trias i Pujol, 08916 Badalona, Spain
2 shared publications
Latest Publications
- 1 February 2021
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 121, 108198
Internalizing and externalizing subtypes in female patients with co-occurring post-traumatic stress disorder and substance use disorders
- 1 February 2021
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 121, 108198
Internalizing and externalizing subtypes in female patients with co-occurring post-traumatic stress disorder and substance use disorders
- 1 April 2019
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 99, 73-79
The dissociative subtype of PTSD in women with substance use disorders: Exploring symptom and exposure profiles
- 1 April 2019
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 99, 73-79
The dissociative subtype of PTSD in women with substance use disorders: Exploring symptom and exposure profiles
- 22 February 2018
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 20 (2) , 18
Lithium oder Valproat für Ältere mit Manie?
- 22 February 2018
- Published by Springer Nature in InFo Neurologie + Psychiatrie
- Vol. 20 (2) , 18
Lithium oder Valproat für Ältere mit Manie?
- 1 March 2016
- Published by Elsevier in Neurology, Psychiatry and Brain Research
- Vol. 22 (1) , 18-19
Clinical predictors of interferon-induced depression in HCV-infected patients without psychiatric risk factors
- 1 March 2016
- Published by Elsevier in Neurology, Psychiatry and Brain Research
- Vol. 22 (1) , 18-19
Clinical predictors of interferon-induced depression in HCV-infected patients without psychiatric risk factors
- 28 August 2014
- Published by Springer Nature in DNP - Der Neurologe und Psychiater
- Vol. 15 (9) , 52-62
Bipolare Störung und „unmet-needs“
- 28 August 2014
- Published by Springer Nature in DNP - Der Neurologe und Psychiater
- Vol. 15 (9) , 52-62
Bipolare Störung und „unmet-needs“
- 1 May 2014
- Published by Elsevier in Psychosomatics
- Vol. 55 (3) , 221-234
Antidepressant Pretreatment for the Prevention of Interferon Alfa–Associated Depression: A Systematic Review and Meta-Analysis
- 1 May 2014
- Published by Elsevier in Psychosomatics
- Vol. 55 (3) , 221-234
Antidepressant Pretreatment for the Prevention of Interferon Alfa–Associated Depression: A Systematic Review and Meta-Analysis
- Open Access
- 15 August 2013
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (suppl_2) , S111-S117
Management of Mental Health Problems Prior to and During Treatment of Hepatitis C Virus Infection in Patients With Drug Addiction
Psychiatric comorbidity is a common problem in patients with substance use disorders. Patients with psychiatric diseases and/or substance abuse have an increased risk for hepatitis C virus (HCV) infection. Furthermore, psychiatric problems occur frequently during antiviral treatment and may be associated with the use of interferon alpha (IFN-α) but also with the primary psychiatric condition. As a consequence, substance abuse and/or acute psychiatric problems are still important reasons for nontreatment of chronic HCV infection. However, prospective and controlled data from recent years showed that if an interdisciplinary treatment is provided, patients with substance use disorders and/or psychiatric diseases do not differ regarding sustained virologic response or IFN-α–associated complications such as depression when compared with controls. Moreover, depression as the most important acute IFN-α–associated psychiatric adverse event can be acutely treated or even prevented by antidepressant pretreatment. Other, more rare but severe complications such as mania, psychotic symptoms, or delirium need individual psychiatric interventions.
- 15 August 2013
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 57 (suppl_2) , S111-S117
Open AccessManagement of Mental Health Problems Prior to and During Treatment of Hepatitis C Virus Infection in Patients With Drug Addiction
Psychiatric comorbidity is a common problem in patients with substance use disorders. Patients with psychiatric diseases and/or substance abuse have an increased risk for hepatitis C virus (HCV) infection. Furthermore, psychiatric problems occur frequently during antiviral treatment and may be associated with the use of interferon alpha (IFN-α) but also with the primary psychiatric condition. As a consequence, substance abuse and/or acute psychiatric problems are still important reasons for nontreatment of chronic HCV infection. However, prospective and controlled data from recent years showed that if an interdisciplinary treatment is provided, patients with substance use disorders and/or psychiatric diseases do not differ regarding sustained virologic response or IFN-α–associated complications such as depression when compared with controls. Moreover, depression as the most important acute IFN-α–associated psychiatric adverse event can be acutely treated or even prevented by antidepressant pretreatment. Other, more rare but severe complications such as mania, psychotic symptoms, or delirium need individual psychiatric interventions.
- 1 December 2012
- Published by Elsevier in Journal of Hepatology
- Vol. 57 (6) , 1379-1390
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
- 1 December 2012
- Published by Elsevier in Journal of Hepatology
- Vol. 57 (6) , 1379-1390
Hepatitis C infection, antiviral treatment and mental health: A European expert consensus statement
- 17 July 2012
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 157 (2) , 94-103
Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease
Depression is a major complication during treatment of chronic hepatitis C virus (HCV) infection with interferon-α (IFN-α). It is unclear whether antidepressants can prevent IFN-induced depression in patients without psychiatric risk factors. To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-α in HCV-infected patients without a history of psychiatric disorders. Randomized, multicenter, double-blind, prospective, placebo-controlled, parallel-group trial. (ClinicalTrials.gov registration number: NCT00136318) 10 university and 11 academic hospitals in Germany. 181 HCV-infected patients with no history of psychiatric disorders enrolled between August 2004 and December 2008. Escitalopram, 10 mg/d (n = 90), or placebo (n = 91) administered 2 weeks before and for 24 to 48 weeks during antiviral therapy. The primary end point was the incidence of depression, defined as a Montgomery–Asberg Depression Rating Scale (MADRS) score of 13 or higher. Secondary end points were time to depression, incidence of major depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, quality of life, sustained virologic response, tolerability, and safety. 32% (95% CI, 21% to 43%) of the patients in the escitalopram group developed a MADRS score of 13 or higher compared with 59% (CI, 48% to 69%) in the placebo group (absolute difference, 27 percentage points [CI, 12 to 42 percentage points]; P < 0.001). Major depression was diagnosed in 8% of the patients in the escitalopram group and 19% in the placebo group (absolute risk difference, 11 percentage points [CI, 5 to 15 percentage points]; P = 0.031). Tolerability and safety parameters did not differ between the groups. In the escitalopram group, 56% (CI, 46% to 66%) of patients achieved a sustained virologic response compared with 46% (CI, 37% to 57%) in the placebo group (P = 0.21). Results might not be generalizable to patients with previous psychiatric disease. Some patients withdrew or developed temporary elevated MADRS scores after randomization but before the study medication was started. Prophylactic antidepressant treatment with escitalopram was effective in reducing the incidence and severity of IFN-associated depression in HCV-infected patients without previous psychiatric disease. Roche Pharma and Lundbeck.
- 17 July 2012
- Published by American College of Physicians in Annals of Internal Medicine
- Vol. 157 (2) , 94-103
Escitalopram for the Prevention of Peginterferon-α2a–Associated Depression in Hepatitis C Virus–Infected Patients Without Previous Psychiatric Disease
Depression is a major complication during treatment of chronic hepatitis C virus (HCV) infection with interferon-α (IFN-α). It is unclear whether antidepressants can prevent IFN-induced depression in patients without psychiatric risk factors. To examine whether preemptive antidepressant treatment with escitalopram can decrease the incidence or severity of depression associated with pegylated IFN-α in HCV-infected patients without a history of psychiatric disorders. Randomized, multicenter, double-blind, prospective, placebo-controlled, parallel-group trial. (ClinicalTrials.gov registration number: NCT00136318) 10 university and 11 academic hospitals in Germany. 181 HCV-infected patients with no history of psychiatric disorders enrolled between August 2004 and December 2008. Escitalopram, 10 mg/d (n = 90), or placebo (n = 91) administered 2 weeks before and for 24 to 48 weeks during antiviral therapy. The primary end point was the incidence of depression, defined as a Montgomery–Asberg Depression Rating Scale (MADRS) score of 13 or higher. Secondary end points were time to depression, incidence of major depression according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, quality of life, sustained virologic response, tolerability, and safety. 32% (95% CI, 21% to 43%) of the patients in the escitalopram group developed a MADRS score of 13 or higher compared with 59% (CI, 48% to 69%) in the placebo group (absolute difference, 27 percentage points [CI, 12 to 42 percentage points]; P < 0.001). Major depression was diagnosed in 8% of the patients in the escitalopram group and 19% in the placebo group (absolute risk difference, 11 percentage points [CI, 5 to 15 percentage points]; P = 0.031). Tolerability and safety parameters did not differ between the groups. In the escitalopram group, 56% (CI, 46% to 66%) of patients achieved a sustained virologic response compared with 46% (CI, 37% to 57%) in the placebo group (P = 0.21). Results might not be generalizable to patients with previous psychiatric disease. Some patients withdrew or developed temporary elevated MADRS scores after randomization but before the study medication was started. Prophylactic antidepressant treatment with escitalopram was effective in reducing the incidence and severity of IFN-associated depression in HCV-infected patients without previous psychiatric disease. Roche Pharma and Lundbeck.
- 1 May 2011
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 34 (4) , 403-408
Health-related Quality of Life Before and During Adjuvant Interferon-α Treatment for Patients With Malignant Melanoma (DeCOG-Trial)
Adjuvant treatment with interferon-alpha (IFN-alpha) for patients with malignant melanoma can improve relapse-free and overall survival, but IFN-associated side effects may reduce patient's quality of life. The aim of the study was to prospectively evaluate health-related quality of life (HRQoL) in patients with melanoma before and during Low-Dose IFN-alpha therapy. In a prospective multicenter trial conducted by the Dermatologic Cooperative Oncology Group, 850 patients with cutaneous stage II malignant melanoma received a standard Low-Dose of IFN-alpha-2a. We evaluated HRQoL using the European Organization for Research and Treatment of Cancer Quality of Life Core 30 questionnaire at baseline and after 3, 6, and 12 months of IFN-alpha treatment in 282 patients. Nine of 15 subscales showed significant poorer results after 3 months of adjuvant IFN treatment. Symptoms included reduced physical functioning, reduced cognitive functioning, fatigue, nausea, pain, dyspnea, insomnia, diarrhea, and loss of appetite. We did not find a significant change over time for role, emotional, or social functioning. Only cognitive functioning and dyspnea continuously worsened through the twelfth month. At baseline women had significantly lower scores for physical and emotional functioning and for fatigue compared with men. During treatment, women scored significantly poorer on physical functioning, emotional functioning, fatigue, pain, and constipation subscales. Patients who reported having a bad or very bad QoL before treatment were 5.8 times more likely to discontinue treatment early because of psychiatric problems. We conclude that adjuvant low-dose IFN treatment is associated with significant deterioration of HRQoL. Specific psychosocial care should be offered especially for patients who report lower HRQoL and emotional problems before treatment to prevent early discontinuation.
- 1 May 2011
- Published by Wolters Kluwer Health in Journal of Immunotherapy
- Vol. 34 (4) , 403-408
Health-related Quality of Life Before and During Adjuvant Interferon-α Treatment for Patients With Malignant Melanoma (DeCOG-Trial)
Adjuvant treatment with interferon-alpha (IFN-alpha) for patients with malignant melanoma can improve relapse-free and overall survival, but IFN-associated side effects may reduce patient's quality of life. The aim of the study was to prospectively evaluate health-related quality of life (HRQoL) in patients with melanoma before and during Low-Dose IFN-alpha therapy. In a prospective multicenter trial conducted by the Dermatologic Cooperative Oncology Group, 850 patients with cutaneous stage II malignant melanoma received a standard Low-Dose of IFN-alpha-2a. We evaluated HRQoL using the European Organization for Research and Treatment of Cancer Quality of Life Core 30 questionnaire at baseline and after 3, 6, and 12 months of IFN-alpha treatment in 282 patients. Nine of 15 subscales showed significant poorer results after 3 months of adjuvant IFN treatment. Symptoms included reduced physical functioning, reduced cognitive functioning, fatigue, nausea, pain, dyspnea, insomnia, diarrhea, and loss of appetite. We did not find a significant change over time for role, emotional, or social functioning. Only cognitive functioning and dyspnea continuously worsened through the twelfth month. At baseline women had significantly lower scores for physical and emotional functioning and for fatigue compared with men. During treatment, women scored significantly poorer on physical functioning, emotional functioning, fatigue, pain, and constipation subscales. Patients who reported having a bad or very bad QoL before treatment were 5.8 times more likely to discontinue treatment early because of psychiatric problems. We conclude that adjuvant low-dose IFN treatment is associated with significant deterioration of HRQoL. Specific psychosocial care should be offered especially for patients who report lower HRQoL and emotional problems before treatment to prevent early discontinuation.